Articles On Kazia Therapeutics (ASX:KZA)

The Kazia Therapeutics Ltd (ASX: KZA) share price is edging lower, down 2% in morning trade. Below we take a look at the oncology-focused drug development company’s latest clinical trial update. What update did Kazia provide? Kazia Therape...

The DFCI study (NCT04906096) is an open-label phase II clinical trial of paxalisib in PCNSL and is expected to recruit up to 25 patients and up to two years to complete.

During the March quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March.

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March.

During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March. 

The company gained exclusive global rights to the drug for €1 million (A$1.6 million) upfront, €308 million (A$480 million) in milestones and a tiered single-digit royalty on sales.

ShareCafeThe Week that Was – April 19-23, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so,...

Kazia Therapeutics (ASX:KZA) has entered into a worldwide exclusive licensing agreement and a master services agreement with European company Evotec SE for EVT801, a small molecule, first-in-class oncology drug candidate.

Kazia Therapeutics (ASX:KZA)‘s chief executive says he could do with catching up on sleep after a “whirlwind” seven weeks in which the $185 million cancer-focused Sydney biotech completed three different cross-border licensing deals. Kazia...

Much of Kazia’s operational capacity has opened up with the inclusion of paxalisib in the GBM AGILE study, and the company believes that it can dedicate significant resources to the EVT801 program.

Kazia expects to explore potential uses of EVT801 during the clinical program, including renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer) and soft tissue sarcoma.

ShareCafeKazia Licenses New Oncology Drug Candidate Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology focused drug development company has announced that it has entered into a worldwide exclusive licensing agreement and a mas...

SYDNEY, April 19, 2021 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master...

The ASX finished the day higher but the all time high reached prior to COVID-19 still eludes it. The ASX 200 closed at 7,066 points – 0.03 per cent higher than Friday – although the ASX Emerging Companies Index fell by 0.64 per cent to 2,10...

Small caps have gained again – rising for the fourth day in a row and the 10th time out of 11 sessions. The Small Ordinaries index of the 101st to 300th biggest Australian companies on Friday advanced 17.7 points, or 0.53 per cent to close...

Corporate Connect has increased the company’s share price target from A$2.25 to A$2.60 a share on the back of two recent licensing deals.

Kazia Therapeutics has executed two licensing deals in the space of a month, proving the company is capable of identifying highly attractive partners and negotiating equally attractive deals.

Uranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or next week after bioenergy company Delorean joined the bourse yesterday. There are four IPOs timed for this week, including Delorean (ASX: DE...

Small caps have gained for a sixth straight day, even as their larger peers declined. The Small Ordinaries index of Australia’s 101st to 300th biggest companies finished the week up 6.7 points, or 0.2 per cent, to a fresh 13-year high of 3,...

The Kazia Therapeutics Ltd (ASX: KZA) share price is backtracking today despite announcing encouraging data from its paxalisib phase II study. At the time of writing, the biotech company’s shares are fetching $1.81, down 3.72%. What did Ka...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The health...

Source:Olena Yakobchuk, Shutterstock Summary Oncology-centric healthcare company Kazia Therapeutics has entered into a licensing agreement with a leading Chinese pharmaceutical company. The deal would focus on the development and mark...

The Kazia Therapeutics Ltd (ASX: KZA) share price is shooting for the moon today. The positive movement comes after the company announced a licence agreement to sell a brain cancer treatment in Greater China. Kazia is an oncology-focused b...

SYDNEY, March 29, 2021 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a licensing agreement with Simcere Pharmaceutical Gr...

Today the ASX was down a 0.3% and only materials (resources) and industrials were in positive territory. These two sectors rose by 1.3 per cent and 0.33 per cent respectively. But the ASX 200 fell 0.36 per cent to 6,800 while the ASX Emergi...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Emerging Australia oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced a license agreement for its lead pipeline candidate Cantrixil (TRX-E-002-1).

SYDNEY, March 2, 2021 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with...

ShareCafeKazia Licenses Ovarian Cancer Drug to Swedish Pharmaceutical Company Australian oncology-focused company, Kazia Therapeutics (ASX: KZA, NASDAQ:KZIA) has just announced a license agreement with Swedish speciality pharmaceutical com...

Oasmia Pharmaceutical AB will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer.

The company’s cash balance for the December 2020 quarter is an increase from the A$8.7 million recorded on June 30, 2020, demonstrating a strong period of growth from a financial perspective.

ShareCafeHidden Gems Webinar Recap – Perennial value management, ADV, LKE, KZA Catch up on the full webinar with presentations from Perennial Value Management, Ardiden Limited (ASX: ADV), Lake Resources (ASX: LKE) and Kazia Therapeutics Li...

ShareCafeKazia Therapeutics (ASX:KZA) – Hidden Gems Webinar Presentation   Presenter – James Garner – Chief Executive Officer & Executive Director – Kazia Therapeutics is an innovative oncology-focused biotechnology company. The compan...

Kazia and its collaborators are currently running six clinical studies of paxalisib across multiple different indications.

Kazia and its collaborators are currently running six clinical studies of paxalisib across multiple different indications.

Summary Dual-listed oncology player Kazia Therapeutics commenced recruitment for the GBM AGILE pivotal study. The Company had signed an agreement in October 2020 with GCAR to get paxalisib in GBM AGILE Kazia anticipates opening additi...

Positive data from GBM AGILE is expected to support the registration of paxalisib in the US and other key markets.

The company is developing innovative, high-impact drugs for cancer and has one of the leading assets in the global glioblastoma pipeline with potential to address a US$1.5 billion market.

Bell Potter has maintained its Speculative Buy rating and valuation of A$2.76 per share for Kazia with the current share price at A$1.20.

Bell Potter has maintained its Speculative Buy rating and valuation of A$2.76 per share for Kazia (current share price: A$1.16).

The company's clinical trial of multiple therapies is set to open in the US in the first half of 2021 before its expansion to other countries later in 2021.

Source: Shutterstock Summary Kazia Therapeutics announced the execution of a Letter of Intent with Pacific Pediatric Neuro-Oncology Consortium. As part of the collaboration, a clinical trial would be conducted for multiple therapies,...

The clinical trial will initially open in the US in the first half of 2021, with expansion to other countries in 2021, with talks ongoing on the potential inclusion of Australian sites

The trial returned positive results and the company intends to shift towards partnering activity to continue the drug's development.

09 Dec 2020 - Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.

Edison Investment Research has increased its valuation on Kazia to A$2.04 per share from A$1.54 per share.

The Kazia Therapeutics Ltd (ASX: KZA) share price is one of the best performers on the ASX this past month, almost doubling in value before retreating today by 12% to $1.53. Overall, the drugmaker’s share price has gained over 82% during t...

The Kazia Therapeutics Ltd [ASX:KZA] share price is following an upward trend. While this small-cap biotech may not be trying to treat COVID, they are trying to treat an equally sinister disease: glioblastoma. The post Kazia Therapeutics Sh...